SCHEMBL23760731

SCHEMBL23760731

N#Cc1ccc(N2CC(C(F)(F)F)[C@@H](CN3CCC4(CCCNC4)CC3)C2)c2nccnc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.38
CYP1A2 P05177 2/20 0.38
TLR8 Q9NR97 3/20 0.37
CYP2D6 P10635 4/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
TLR9 Q9NR96 3/20 0.34
TLR7 Q9NYK1 3/20 0.34
ALDH1A1 P00352 4/20 0.33
MAPK1 P28482 2/20 0.33
RET P07949 4/20 0.33
HSD17B10 Q99714 2/20 0.33
TSHR P16473 2/20 0.33
ROCK2 O75116 1/20 0.33
ROCK1 Q13464 1/20 0.33
CDC42BPA Q5VT25 1/20 0.33
CDC42BPB Q9Y5S2 1/20 0.33
HPGD P15428 1/20 0.33
SYK P43405 1/20 0.32
CHEK1 O14757 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23628755 1.00 CYP3A4 (0.38) CYP3A4CYP1A2TLR8CYP2D6CYP2C9
SCHEMBL23628810 0.95 TLR8 (0.38) CYP3A4CYP1A2TLR8TLR9TLR7
SCHEMBL23760718 0.95 TLR8 (0.38) CYP3A4CYP1A2TLR8TLR9TLR7
SCHEMBL23628819 0.90 TLR8 (0.50) CYP3A4CYP1A2TLR8CYP2D6CYP2C9
SCHEMBL23760741 0.90 TLR8 (0.50) CYP3A4CYP1A2TLR8CYP2D6CYP2C9
SCHEMBL23760663 0.90 TLR8 (0.37) CYP3A4CYP1A2TLR8CYP2D6CYP2C9
SCHEMBL23628828 0.90 TLR8 (0.37) CYP3A4CYP1A2TLR8CYP2D6CYP2C9
SCHEMBL23628817 0.90 TLR8 (0.37) CYP3A4TLR8CYP2D6CYP2C9CYP2C19
SCHEMBL23628870 0.86 TLR8 (0.36) CYP3A4CYP1A2TLR8CYP2D6CYP2C9
SCHEMBL23628860 0.86 TLR8 (0.41) TLR8TLR9TLR7ALDH1A1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253575-A1 PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2021-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253575-A1 PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE ARG1, PRMT1, PADI1 CYP3A4 3575/4885CYP1A2 2291/4885TLR8 1800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.